A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in
Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days,
to adult patients with advanced solid tumors who have progressed despite standard therapy or
for whom standard systemic therapy does not exist.